Novo Nordisk wins Singapore approval for Wegovy in MASH with liver fibrosis

Novo Nordisk announced that Singapore’s Health Sciences Authority approved Wegovy (semaglutide 2.4 mg) as the first treatment in Singapore for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (F2–F3).

The approval is based on the 72-week interim analysis of the ESSENCE phase 3 trial, where Wegovy outperformed placebo on both key liver endpoints.

Reported trial results included 63% of patients achieving resolution of steatohepatitis without worsening fibrosis versus 34% on placebo, and 37% achieving at least a one-stage improvement in liver fibrosis without worsening steatohepatitis versus 22% on placebo.

Novo said the safety profile was consistent with prior semaglutide data, and the study will continue to 240 weeks to assess longer-term outcomes.

The Singapore approval follows broader momentum for Wegovy in MASH, including regulatory recognition in other markets.